Novavax (NVAX) reported Q2 2026 revenue of $57M and a net loss of $53M, indicating significant profitability pressure. The company pointed to progress with its Sanofi partnership, increased use of its Matrix-M adjuvant platform, and ongoing cost reductions, but the results remain weighed down by continued losses.
Novavax (NVAX) reported Q2 2026 revenue of $57M and a net loss of $53M, indicating significant profitability pressure. The company pointed to progress with its Sanofi partnership, increased use of its Matrix-M adjuvant platform, and ongoing cost reductions, but the results remain weighed down by continued losses.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
